These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22337328)

  • 1. [Prognostic relevance of body mass index and rash for patients with metastatic non-small-cell lung cancer under therapy with erlotinib].
    Böker B; Lüders H; Grohé C
    Pneumologie; 2012 Feb; 66(2):89-95. PubMed ID: 22337328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skin rash as a surrogate marker of clinical response of targeted therapy using gefitinib in advanced or metastatic non-small-cell lung cancer--a retrospective study.
    Acharyya S; Sau S; Dasgupta P; Chakraborty A; Gangopadhyay S
    J Indian Med Assoc; 2012 Jul; 110(7):474-6, 493. PubMed ID: 23520673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The applicability of a predictive index for second- and third-line treatment of unselected non-small-cell lung cancer patients.
    Wojas-Krawczyk K; Krawczyk P; Mlak R; Kucharczyk T; Kowalski DM; Krzakowski M; Milanowski J
    Respiration; 2011; 82(4):341-50. PubMed ID: 21242665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatment.
    Kim ST; Lee J; Sun JM; Park YH; Ahn JS; Park K; Ahn MJ
    Oncology; 2010; 79(1-2):78-84. PubMed ID: 21071994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
    Johnson JR; Cohen M; Sridhara R; Chen YF; Williams GM; Duan J; Gobburu J; Booth B; Benson K; Leighton J; Hsieh LS; Chidambaram N; Zimmerman P; Pazdur R
    Clin Cancer Res; 2005 Sep; 11(18):6414-21. PubMed ID: 16166415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
    Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
    Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA drug approval summary: erlotinib (Tarceva) tablets.
    Cohen MH; Johnson JR; Chen YF; Sridhara R; Pazdur R
    Oncologist; 2005 Aug; 10(7):461-6. PubMed ID: 16079312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
    Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
    Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line.
    Faehling M; Eckert R; Kuom S; Kamp T; Stoiber KM; Schumann C
    Oncology; 2010; 78(3-4):249-58. PubMed ID: 20523085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis in patients with non-small cell lung cancer who received erlotinib treatment and subsequent dose reduction due to skin rash.
    Takashima N; Kimura T; Watanabe N; Umemura T; Katsuno S; Arakawa K; Fukatsu M; Nakamura N; Nishiyama O; Kataoka K; Kondoh Y; Taniguchi H
    Onkologie; 2012; 35(12):747-52. PubMed ID: 23207620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.
    Lilenbaum R; Axelrod R; Thomas S; Dowlati A; Seigel L; Albert D; Witt K; Botkin D
    J Clin Oncol; 2008 Feb; 26(6):863-9. PubMed ID: 18281658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three years of erlotinib in routine practice for non-small cell lung cancer in South East Scotland.
    Ironside JA; English JF; Kerr GR; Price A; Little FA; Erridge SC; Mackean MJ
    Clin Oncol (R Coll Radiol); 2010 Sep; 22(7):550-3. PubMed ID: 20627674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
    Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
    Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter observational study of erlotinib therapy (OBSTAR) for non small-cell lung cancer: a GFPC study.
    Vergnenègre A; Monnet I; Chouaïd C; Hureaux J; Mazières J; Quéré G; Lombard JN; Cumin I; Abdiche S; Ejnaini CN; Bonnabau H; Decroisette Ch;
    Lung Cancer; 2011 Nov; 74(2):264-7. PubMed ID: 21571389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
    Guttman-Yassky E; Mita A; De Jonge M; Matthews L; McCarthy S; Iwata KK; Verweij J; Rowinsky EK; Krueger JG
    Eur J Cancer; 2010 Jul; 46(11):2010-9. PubMed ID: 20621734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of smoking on histologic type and the efficacy of adjuvant chemotherapy in resected non-small cell lung cancer.
    Zhang Z; Xu F; Wang S; Li N; Wang C
    Lung Cancer; 2008 Jun; 60(3):434-40. PubMed ID: 18036699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials.
    Petrelli F; Borgonovo K; Cabiddu M; Lonati V; Barni S
    Lung Cancer; 2012 Oct; 78(1):8-15. PubMed ID: 22795701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
    Herbst RS; Prager D; Hermann R; Fehrenbacher L; Johnson BE; Sandler A; Kris MG; Tran HT; Klein P; Li X; Ramies D; Johnson DH; Miller VA;
    J Clin Oncol; 2005 Sep; 23(25):5892-9. PubMed ID: 16043829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
    Jänne PA; Gurubhagavatula S; Yeap BY; Lucca J; Ostler P; Skarin AT; Fidias P; Lynch TJ; Johnson BE
    Lung Cancer; 2004 May; 44(2):221-30. PubMed ID: 15084387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.